FDA Accepts Application for Fluvoxamine Maleate by APPCO
The FDA has accepted the application ANDA220328 for Fluvoxamine Maleate submitted by APPCO.
Asset / Drug
Drug and asset intelligence for APPCO with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.